PBEInvesco Biotechnology & Genome ETF
Tracks the investment results of the Dynamic Biotech & Genome Intellidex Index.
By Invesco · Launched 2005
Annual Cost
0.59%
#3,222 of 6,040 · average
Fund Size
$471M
#1,711 of 6,040 · large
Return (1Y)
+39.9%
Track Record
21 years
#233 of 6,040 · established
Performance
Total-return NAV · USDGrowth of $10,000
$12,495+24.9%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaCap
Multi cap
Strategy
Index tracking
Sector
Health careFocus
Biotech & Genomics
Index tracked
Dynamic Biotech & Genome Intellidex Index
Holdings
By weightConcentration
Top 10 holdings = 55.7% of fundmoderately concentrated
Invesco Private Prime Fund
10.9%
United Therapeutics Corp.
6.3%
Illumina, Inc.
5.4%
Biogen Inc.
5.1%
Incyte Corp.
4.9%
Alnylam Pharmaceuticals, Inc.
4.8%
Regeneron Pharmaceuticals, Inc.
4.8%
Amgen Inc.
4.7%
Gilead Sciences, Inc.
4.6%
Invesco Private Government Fund
4.2%
Asset allocation
Stocks
100.0%
Cash
0.0%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
19.1%Moderate
Year-on-year price swings
Max drawdown
-37.8%Severe
Worst peak-to-trough loss
Sharpe (3Y)
0.69Decent risk-adjusted returns
Sortino (3Y)
1.02Good downside protection
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Tracks the investment results of the Dynamic Biotech & Genome Intellidex Index.
- Strategy
- Invests at least 90% of total assets in common stocks of U.S. biotechnology and genome companies, employing full replication to track the Dynamic Biotech & Genome Intellidex Index. Concentrates investments in the biotechnology and genome industry, with market capitalizations from $787.1 million to $150.1 billion.
- Inception date
- June 23, 2005
- Fund family
- Invesco
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save PBE to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18